Skip to main content

Market Overview

Fortress Biotech's Partner Offloads CUTX-101 To Sentynl Therapeutics

  • Fortress Biotech Inc's (NASDAQ: FBIO) partner company, Cyprium Therapeutics Inc, has agreed to sell CUTX-101 to Sentynl Therapeutics Inc.
  • CUTX-101 is a copper histidinate product candidate for the treatment of Menkes disease. The condition is characterized by sparse and depigmented hair, connective tissue problems, severe neurological symptoms, and neurodevelopmental delays.
  • Under the agreement, Cyprium is eligible to receive up to $20 million in upfront development and regulatory cash milestones through marketing application approval, as well as potential sales milestones.
  • Royalties on CUTX-101 net sales ranging from the mid-single digits up to the mid-twenties are also payable.
  • Cyprium will retain the development responsibility of CUTX-101 through approval of the marketing application by the FDA. Sentynl will be responsible for the commercialization of CUTX-101 and progressing newborn screening activities.
  • Sentynl will begin the rolling submission of the marketing application to the FDA this year.
  • Price Action: FBIO gained 1.88% at $3.8 in premarket trading on the last check Wednesday.

Related Articles (FBIO)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Penny Stocks Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at